AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01673035 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BSM, stress management and applied relaxation
Description: BSM, this intervention comprises structured exercises aimed at reducing stress and controlling the anxiety response. One main component is applied relaxation.
Study NCT04733365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERIC protocol
Description: ERIC protocol is an aerobic exercise protocol with 5 levels of intensity
Study NCT03849742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03849742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03849742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Receive Uber rides
Study NCT01038024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 tablet composed of antioxidants and minerals
Description: 1 tablet daily
Study NCT03041246 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor fascial mobilization
Description: The manual manipulation of the pelvic floor involves intra vaginal superficial as well as pelvic skin area pressure points.
Study NCT03309358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled SNSP113
Description: A single ascending dose of inhaled SNSP113 will be administered to healthy subjects and subjects with stable cystic fibrosis.
Study NCT03309358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: A single dose of inhaled placebo control will be administered to healthy subjects and subjects with stable cystic fibrosis.
Study NCT00775138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for Cohort 2
Description: Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Study NCT03869931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate 100 mg or 300 mg (according to CrCl)
Study NCT03969589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reproductive Life Planning-Mental Health (RLP-MH) Intervention
Description: RLP-MH intervention is comprised of two parts: 1) an in-person interactive session in which the participant works with an RLP-MH facilitator to explore pregnancy intentions and RLP goals, consider important factors that impact those goals (e.g. mental health and physical health conditions, psychosocial and lifestyle factors, values, preferences), and identify personal action steps to address RLP goals and 2) a 15-20 minute follow-up session in person or by phone one month later to discuss progress in addressing RLP goals.
Study NCT03969589 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Written Materials on Reproductive Life Planning
Description: Participants will receive written materials on reproductive life planning, contraception, and VA resources. Participants will be given the materials and study staff will briefly discuss the content with the participant.
Study NCT02194634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept
Description: Intravitreal injection of 0.5 mg Conbercept at first month, then repeated as needed.
Study NCT02194634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham injection
Description: Sham intravitreal injection at first month, then repeated as needed.
Study NCT02194634 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Laser treatment at first month, then repeated as needed.
Study NCT02194634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham laser
Description: Sham laser at first month, then repeated as needed.
Study NCT03446664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microburst Stimulation
Description: Implantable generator with new stimulation feature under study to determine the safety and effectiveness of device stimulation on different seizure types.
Study NCT02797496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asymmetric Motor Strengthening
Description: In the Asymmetric Motor Strengthening program, the principle is to concomitantly reinforce the body openers and stretch the body closers. One alternates two types of practice during a session. Active exercises consist of fatiguing series of rapid alternating movements against light weights working on movements of extension/abduction/external rotation/supination. Stretch postures consists of short 1-2 minutes bouts of flexor/internal rotator/adductor/pronator stretch. The duration of rehabilitation program is 8 weeks.
Study NCT02797496 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Conventional therapy will include general stretch, strengthening and balance exercises, respiratory exercises and relaxation methods.
Study NCT03674879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Patient contact attempted with text message.
Study NCT00498888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tolterodine
Description: Detrusitol SR 4 mg, 1 capsule for a day, 3 months.
Study NCT00498888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bladder training
Description: Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for educate and schedule voiding regimen.
Study NCT00498888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor muscle training
Description: Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for reinforced pelvic floor muscles.
Study NCT00498888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor rehabilitation
Description: The Pelvic floor rehabilitation protocol based on bladder training protocol and PFMT and lifestyle advice and information about good bladder and bowel habits. Four visits in 3 months was made with pelvic floor physical therapist, who is trained in the procedure.
Study NCT01028131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-delivered brief intervention (5As)
Description: After completing the brief assessment battery, participants will interact with the computer for approximately 20 minutes, with structure being based on the Five A model and Motivational Interviewing.
Study NCT01028131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants randomized by the computer into this condition will view a 20-minute music and tv videos after completing the brief assessment. The research assistant will then briefly describe the CM process, with a period for questions to assure understanding. The CM condition will involve participant-initiated submission of urine samples at prenatal visits. Clinic staff will have no responsibility for the CM component other than calling research staff when a participant wishes to submit a sample. Clinic staff will not schedule any new, additional, or unnecessary prenatal visits.
Study NCT02305498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vigorous yoga practice
Study NCT02305498 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restorative (gentle) yoga practice
Study NCT00512902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: All subjects will receive gleevec. Subjects will have a clinic visit every 2 weeks for the first 20 weeks and then they will have one every 4 weeks for the remainder of the study. Gleevec will be taken by mouth everyday. It will be increased to a maximum of 600 mg every day. It will be increased 100 mg at each visit for the first 12 weeks. Your participation may last up to 1 year and participants will have approximately 18 clinic visits.
Study NCT00512902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Up to 600 mg QD PO for up to 1 year.
Study NCT02782026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exhaled Breath Olfactory Signature (Artificial Nose)
Study NCT03164330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workplace Wellness Program
Description: Treatment group members will then be offered the opportunity to participate in a biometric screening and health risk assessment (biometric screening + HRA), and -- conditional on completing an biometric screening + HRA -- up to two, semester-long wellness programs. Treatment group members will be offered varying levels of cash reward for completing the biometric screening + HRA (none, moderate, high), and an additional cash reward for completing each wellness activity (low, high), for a total of 6 treatment cells. Follow-up surveys and biometric screenings will be administered one year later, among a subset of control and treatment group members.
Study NCT03164330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biometric Screening/HRA - No Compensation
Description: The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. No compensation for completion.
Study NCT03164330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biometric Screening/HRA - Moderate Compensation
Description: The biometric test will measure: (1) anthropometrics such as height, weight, \& waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); \& (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. Moderate compensation for completion.
Study NCT03164330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biometric Screening/HRA - High Compensation
Description: The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. High compensation for completion.
Study NCT03164330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Activities - Low Compensation
Description: Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. Low compensation for each class.
Study NCT03164330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Activities - High Compensation
Description: Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. High compensation for each class.
Study NCT04847180 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: The biopsy will be performed at the level of the capsular fold located just above the area devoid of cartilage in the postero-superior region of the humeral head, near the area where Hill Sachs notches occur.
Study NCT01890863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate / Salmeterol Xinafoate DISKUS
Description: Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via DISKUS (Ddpi) device.
Study NCT01890863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate / Salmeterol Xinafoate ROTACAP
Description: Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via ROTAHALER (Rdpi) device.
Study NCT00699998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 300 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study
Study NCT00699998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: 30 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight and age), oral, once daily as maintenance dose through end of study
Study NCT00699998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Commercially-available Aspirin
Description: Low-dose aspirin, oral, as prescribed by physician through end of study
Study NCT04936347 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cold knife
Description: Transcervical resection of adhesions is performed with scissors to restore the shape of uterine cavity, promote the regeneration and repair of endometrium, and ultimately improve the reproductive prognosis of patients.
Study NCT04936347 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: hot knife
Description: Transcervical resection of adhesions is performed with bipolar electric cutting to restore the shape of uterine cavity, promote the regeneration and repair of endometrium, and ultimately improve the reproductive prognosis of patients.
Study NCT03821194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gua sha
Description: Scrape the skin around the knee joint
Study NCT03821194 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hot pack
Description: hot pack
Study NCT01912534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valsartan
Description: 40, 80 and 160 mg tablets of Valsartan
Study NCT01912534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: 40, 80 and 160 mg tablets of Valsartan
Study NCT01912534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo
Study NCT01912534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo
Study NCT04847180 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: The biopsy will be performed at the level of the capsular fold located just above the area devoid of cartilage in the postero-superior region of the humeral head, near the area where Hill Sachs notches occur.
Study NCT01829594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case management
Description: Nurses and a physiotherapist (PT) worked as case managers (CM). The intervention lasted 12 months and comprised 4 dimensions. The first was traditional CM tasks: assessment, planning, monitoring, care coordination and evaluation. Home visits were made at least once a month. The second and third was general and specific information related to the participants' situation. The fourth part included aspects of continuity and safety. The PT also paid home visits and made an assessment regarding physical function and balance. The intervention consisted of multidimensional prevention of falls and/or consequences of falls, and supporting and motivating the participant to increased physical activity. When those in the control group had participated for 12 months they were offered the intervention.
Study NCT03294187 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Wrist-worn wearables
Description: See arm/group description.
Study NCT01455194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: During the treatment period subjects will inhale two puffs of either 40, 80 or 160 μg ciclesonide in the morning and the evening (corresponding to a total daily dose of 160, 320 or 640 μg)
Study NCT00699998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Commercially-available Aspirin
Description: Low-dose aspirin, oral, as prescribed by physician through end of study
Study NCT02459938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon (ZP-Glucagon)
Description: chemically synthesized glucagon as delivered via transdermal microneedle patch system for 30 minutes
Study NCT01922843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP001 softgel capsules
Study NCT02459938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon (GlucaGen)
Description: recombinant glucagon administered via subcutaneous injection
Study NCT01922843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05060965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: Nicotine replacement therapy
Study NCT05060965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Description: Nicotine replacement therapy
Study NCT05060965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Nicotine replacement therapy
Study NCT05060965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maryland Quitline
Description: Telephone-based tobacco cessation service
Study NCT05060965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: John Hopkins Tobacco Treatment Clinic
Description: Clinic-based tobacco cessation service
Study NCT02929082 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IRM with a 5-minute- additional sequence to measure FRM
Description: IRM with a 5-minute- additional sequence to measure FRM for patients in group 1,2 and 3
Study NCT01699074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 gram of White Korean Ginseng
Description: 1 gram of White Korean Ginseng
Study NCT01699074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3 grams of White Korean Ginseng
Description: 3 grams of White Korean Ginseng
Study NCT01699074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 6 grams of White Korean Ginseng
Description: 6 grams of White Korean Ginseng
Study NCT01699074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 3 grams of Wheat Bran Control
Description: 3 grams of Wheat Bran Control
Study NCT01699074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 500mg of Korean Red Ginseng
Description: 500mg of Korean Red Ginseng
Study NCT00772681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and cisplatin
Description: 3 cycles of docetaxel 75mg/m2 and 100mg/m2 cisplatin combination every 3 weeks
Study NCT00727558 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nelfilcon A
Description: spherical soft contact lens
Study NCT00727558 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: narafilcon A
Description: spherical soft contact lens
Study NCT02342080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training sessions
Description: A group with spinal cord injury will be trained in a 30-minute session 5 times weekly for 6 weeks. Each session will be supervised by qualified staff. Patients will undergo training with gradual increase in load and speed, according to the tolerance of each patient. The body weight support progression will start at 50 % of the patient body weight. It will be changed every 2 weeks and the load will decrease 10%. The progression of speed may be accompanied during the training period.
Study NCT02342080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat system (Hocoma AG Switzerland)
Description: For the robot locomotion therapy, the Lokomat system (Hocoma AG Switzerland) will be used.
Study NCT02456857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT02456857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT02456857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02456857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV